Search Results (3)

To address greenhouse gas (GHG) emissions from the maritime sector, the European Union (EU) has introduced the FuelEU Maritime regulation to incentivize ships to adopt diversified compliance pathways and energy solutions. This study aims to determine the optimal alternative fuel configurations for dual-fuel ships of different types under environmental, economic, and regulatory constraints. An integrated environmental and cost assessment model from a well-to-wake (WtW) perspective to systematically evaluate the environmental benefits and economic feasibility of fossil-based, bio-based, and renewable electricity-based alternative fuels applied in dual-fuel ships. By incorporating the PROMETHEE II method within a multi-criteria decision analysis (MCDA) framework, together with the CRITIC objective weighting method, the study enables a robust ranking of alternative fuel configurations across three key dimensions: environmental performance, cost feasibility, and regulatory compliance. The results indicate that, regardless of ship type, the very low sulfur fuel oil (VLSFO) + marine gas oil (MGO) and VLSFO + methanol (MEOH) combinations fail to meet the GHG intensity targets for 2025–2050. Only the VLSFO + electrolytic liquid hydrogen (E-LH₂) and VLSFO + electrolytic ammonia (E-NH₃) configurations are compliant. Although e-fuels incur the highest annual costs, the EU compliance penalty associated with fossil fuels increases exponentially. In contrast, e-fuels retain long-term cost advantages, ultimately driving a sector-wide transition toward e-fuel-dominated energy structures by 2050. Their superior environmental performance and regulatory compatibility emerge as the core drivers of the maritime energy transition. Full article

Hepatitis B virus (HBV) replication is controlled by four promoters (preS1, preS2, Cp, and Xp) and two enhancers (EnhI and EnhII). EnhII stimulates Cp activity to regulate the transcriptions of precore, core, polymerase, and pregenomic RNAs, and therefore, EnhII/Cp is essential for the regulation of HBV replication. This study revealed a distinct mechanism underlying the suppression of EnhII/Cp activation and HBV replication. On the one hand, the sex determining region Y box2 (SOX2), a transcription factor, is induced by HBV. On the other hand, SOX2, in turn, represses the expression levels of HBV RNAs, HBV core-associated DNA, hepatitis B surface antigen (HBsAg), and hepatitis B e antigen (HBeAg), thereby playing an inhibitory role during HBV replication. Further studies indicated that SOX2 bound to the EnhII/Cp DNA and repressed the promoter activation. With the deletion of the high mobility group (HMG) domain, SOX2 loses the ability to repress EnhII/Cp activation, viral RNA transcription, HBV core-associated DNA replication, HBsAg and HBeAg production, as well as fails to enter the nucleus, demonstrating that the HMG domain is required for the SOX2-mediated repression of HBV replication. Moreover, SOX2 represses HBsAg and HBeAg secretion in BALB/c mice sera, and attenuates HBV 3.5 kb RNA transcription and hepatitis B virus core protein (HBc) production in the liver tissues, demonstrating that SOX2 suppresses HBV replication in mice. Furthermore, the results revealed that the HMG domain was required for SOX2-mediated repression of HBV replication in the mice. Taken together, the above facts indicate that SOX2 acts as a new host restriction factor to repress HBV replication by binding to the viral EnhII/Cp and inhibiting the promoter activation through the HMG domain. Full article